EcoDrugPlus

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSPTIG00000012974
Gene Symbol: ADRM1
2 Cross references
255 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSPTIG00000010966
Gene Symbol: AKT2
2 Cross references
253 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSPTIG00000021068
Gene Symbol: AKT3
2 Cross references
201 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSPTIG00000017777
Gene Symbol: ALK
2 Cross references
194 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSPTIG00000014438
Gene Symbol: ABCB1
2 Cross references
161 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSPTIG00000017813
Gene Symbol: ABCC1
2 Cross references
201 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSPTIG00000012009
Gene Symbol: ABCC8
1 Cross references
237 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSPTIG00000006749
Gene Symbol: ABCC9
2 Cross references
229 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSPTIG00000017666
Gene Symbol: ATP4A
2 Cross references
183 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSPTIG00000016958
Gene Symbol: ATP4B
2 Cross references
184 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSPTIG00000020868
Gene Symbol: ATP1A1
2 Cross references
322 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 2

Ensembl ID : ENSPTIG00000008674
Gene Symbol: ATP1A2
2 Cross references
205 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).